Study of acalabrutinib and bortezomib for platelet transfusion problems
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests two drugs (acalabrutinib and bortezomib) to help people with blood cancer whose platelet transfusions aren't working because their immune system attacks the transfused platelets. It aims to improve platelet counts and reduce bleeding risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 65.
- You have a blood cancer (like leukemia, lymphoma, or myeloma) and platelet transfusions haven't been working well.
- A blood test shows very high levels of HLA antibodies (a type of immune protein) that can block platelets.
- You are generally able to care for yourself (ECOG 0-3) and expected to live more than 6 months.
- You do not have active serious bleeding, an out-of-control infection, or other major organ problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs for people with CLL or SLL whose cancer returned after first treatment with a similar type of therapy. The goal is to see if this approach works well with a fixed treatment duration.
This trial tests adding acalabrutinib (a targeted therapy) to standard chemotherapy (R-CHOP) for people with mantle cell lymphoma who have not had treatment before and cannot have a stem cell transplant. The goal is to see if the combination works better than R-CHOP alone.
This Phase 2 trial tests whether bortezomib can safely increase platelet counts in adults with immune thrombocytopenia (ITP) that keeps coming back or doesn’t respond to standard treatments. It’s for people with very low platelets who still need treatment despite prior medicines.
This Phase 2 study looks at zanubrutinib, a new medication, in people with immune thrombocytopenia (ITP) whose low platelet count has lasted more than 3 months and has not responded to prior steroid and other treatments. It may help raise platelets and reduce bleeding risk when other therapies have not worked.
This trial tests a new drug, INCA035784, for people with myeloproliferative neoplasms (MPNs), a group of blood cancers. It may help if your MPN is called myelofibrosis (MF) or essential thrombocythemia (ET) and has a specific genetic change (CALR mutation), and you've already tried other treatments.
This study tests different doses of a drug called zanubrutinib (a BTK inhibitor) to find the best dose for adults with newly diagnosed ITP that hasn't been treated yet. It aims to see if this drug can safely boost platelet counts and reduce bleeding symptoms.
Hear when a new Hematological Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.